GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 22-35•Healthy volunteers

Primary endpoints

•Area Under Concentration•AUC (0-∞) of Metoprolol with Retatrutide•PK: Maximum Concentration (Cmax) of Metoprolol

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06808802

Org study ID27303

Secondary IDJ1I-MC-GZQEEli Lilly and Company

Timeline

Milestones

Study start2025-02-03actual

Study first posted2025-02-05actual

Primary completion2025-04-15actual

Study completion2025-04-15actual

Last update posted2025-06-05actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and vital signs

•Have a body mass index (BMI) within the range 22.0 to 35.0 kilogram per square meter (kg/m2) (inclusive) at screening

Exclusion criteria

•Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have glycated hemoglobin (HbA1c) greater than or equal to (≥) 6.5% (48 millimole/mole (mmol/mol)

•Have a mean supine screening pulse rate of less than 45 or greater than 100 beats per minute (bpm) from 2 assessments. If a repeat measurement (mean of 2 assessments) shows values within the range of 45 to 100 bpm, the participant may be included in the trial

•Have significant history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data

•Had any of the following cardiovascular conditions prior to screening: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalization due to congestive heart failure

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

5 endpoints

Primary/protocol endpoint

Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol

Time frame:Day 1 to Day 3

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide

Time frame:Day 9 to Day 11

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Maximum Concentration (Cmax) of Metoprolol

Time frame:Day 1 to Day 3

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Metoprolol with Retatrutide

Time frame:Day 9 to Day 11

Cmax

concentration, descriptive

Secondary/protocol endpoint

Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs)

Time frame:Baseline to Day 44

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.